METHODS: We reviewed randomized controlled trials of individuals aged 40 years or older. We systematically searched PubMed/MEDLINE, EMBASE, CINAHL, PsycINFO, and Cochrane Library databases. We used the restricted cubic splines model for non-linear dose-response meta-analysis in terms of the standardized mean difference with 95% confidence intervals.
RESULTS: The current meta-analysis on 24 studies (n 9660; follow-up 3 to 36 months) found that the beneficial effect on executive function demonstrates an upward trend within the initial 12 months of intervention. This effect is prominently observed with a daily intake surpassing 500 mg of n-3 PUFA and up to 420 mg of eicosapentaenoic acid (EPA). Furthermore, these trends exhibit heightened significance in regions where the levels of blood docosahexaenoic acid (DHA) + EPA are not very low.
CONCLUSIONS: Supplementation of n-3 PUFA may confer potential benefits to executive function among the middle-aged and elderly demographic, particularly in individuals whose dietary DHA + EPA level is not substantially diminished.
方法:我们回顾了40岁以上人群的随机对照试验。我们系统地搜索了PubMed/MEDLINE,EMBASE,CINAHL,PsycINFO,和Cochrane图书馆数据库。我们使用限制性三次样条模型进行非线性剂量效应荟萃分析,以95%置信区间的标准化平均差为依据。
结果:当前对24项研究(n9660;随访3至36个月)的荟萃分析发现,对执行功能的有益影响在干预的最初12个月内呈上升趋势。在每日摄入超过500mg的n-3PUFA和高达420mg的二十碳五烯酸(EPA)的情况下,显著观察到这种效果。此外,这些趋势在血液中二十二碳六烯酸(DHA)+EPA水平不是很低的地区表现出更高的重要性.
结论:补充n-3PUFA可能会对中老年人群的执行功能产生潜在的益处,特别是在饮食中DHA+EPA水平没有显著降低的个体中。